[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"desmoid-fibromatosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:desmoid-fibromatosis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,83,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":42},"100384107","observing-people-with-desmoid-type-fibromatosis-100384107",false,"NCT04281381","Observing People With Desmoid-Type Fibromatosis","A Prospective Analysis of Active Observation in Patients With Desmoid-Type Fibromatosis","Inclusion Criteria:\n\n* Clinical diagnosis of desmoid fibromatosis, either new or newly recurrent. Both patients with sporadic and FAP-associated disease will be eligible for inclusion. Patients with clinical diagnosis of desmoid (as assessed by MSK physician) but without pathologic diagnosis may be enrolled on the study to facilitate acquisition of appropriately protocoled baseline scans and allow for biospecimen collection; these patients will be replaced for purposes of analysis if pathology does not confirm clinical diagnosis.\n* At least 18 years of age.\n* Able to undergo cross-sectional imaging by either MRI or CT with intravenous contrast\n* Disease detectable on cross-sectional imaging with target lesion measuring \\>\u002F= 1 cm\n* Eligible for management by active observation as assessed by primary MSK care provider\n* Willing and able to sign an informed consent document\n\nExclusion Criteria:\n\n* Symptomatic desmoid fibromatosis requiring narcotic pain control, resulting in intestinal fistulization, or requiring inpatient admission during the 3 months prior to enrollment\n* Patients with intraabdominal desmoids greater than 7cm in diameter or localized within 1cm of the central mesenteric vessels and those with tumors in the head and neck\n* KPS performance status \\\u003C\u002F= 70 if performance status is limited due to tumor. Patients with low KPS performance status related to co-morbidities but without symptoms related to the tumor will be eligible for enrollment.\n* Age less than 18 years old\n* Strict contraindication for both cross-sectional MRI and CT imaging with intravenous contrast (e.g., as per standard institutional protocols regarding renal insufficiency or MRI incompatible implanted devices; patients requiring pre-medication to prevent contrast reactions will be eligible for study)\n* Unable to grant reliable informed consent\n* Ongoing systemic treatment for desmoid fibromatosis","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to closely observe people with desmoid-type fibromatosis over 1 months.",[24],"Desmoid Fibromatosis",[26,24,27,28,29,30],"Desmoid-Type Fibromatosis","Desmoid","Fibromatosis","20-026","Memorial Sloan Kettering Cancer Center","RECRUITING","2026-05-13",{"date":34,"type":35},"2026-05-15","ACTUAL",{"date":37,"type":35},"2020-02-19",{"date":39,"type":20},"2027-02-19",{"name":30,"class":41},"OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100239986","project-every-child-for-younger-patients-with-cancer-100239986","NCT02402244","Project: Every Child for Younger Patients With Cancer","The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study","Inclusion Criteria:\n\n* Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem\n* Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority\n* Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:\n\n  * All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one \"1\" (borderline), two \"2\" (carcinoma in situ) or three \"3\" (malignant)\n  * All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant\n  * All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant\n  * The following other benign\u002Fborderline conditions:\n\n    * Mesoblastic nephroma\n    * Teratomas (mature and immature types)\n    * Myeloproliferative diseases including transient myeloproliferative disease\n    * Langerhans cell histiocytosis\n    * Lymphoproliferative diseases\n    * Desmoid tumors\n    * Gonadal stromal cell tumors\n    * Neuroendocrine tumors including pheochromocytoma\n    * Melanocytic tumors, except clearly benign nevi\n    * Ganglioneuromas\n* Subjects must be =\\\u003C 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \\[NCTN\\]) therapeutic study, for which there is a higher upper age limit\n* All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission\n\n  * If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1","25 Years",{"count":52,"type":20},75000,"This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.",[55,56,57,58,59,60,61,62,24,63,64,65,66,67,68,69,70,71],"Adrenal Gland Pheochromocytoma","Carcinoma In Situ","Central Nervous System Neoplasm","Childhood Immature Teratoma","Childhood Kidney Neoplasm","Childhood Langerhans Cell Histiocytosis","Childhood Mature Teratoma","Congenital Mesoblastic Nephroma","Ganglioneuroma","Lymphoproliferative Disorder","Malignant Neoplasm","Malignant Solid Neoplasm","Melanocytic Neoplasm","Myeloproliferative Neoplasm","Neoplasm of Uncertain Malignant Potential","Neuroendocrine Neoplasm","Stromal Neoplasm","2026-05-01",{"date":74,"type":35},"2026-05-05",{"date":76,"type":35},"2015-11-03",{"date":78,"type":20},"2030-12-31",{"name":80,"class":81},"Children's Oncology Group","NETWORK",278,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":42},"100588783","treatment-of-desmoid-fibromatosis-with-arterial-embolization-100588783","NCT06945887","Treatment of Desmoid Fibromatosis With Arterial Embolization","Treatment of Desmoid Fibromatosis With Arterial Embolization: Retrospective and Prospective Observational Study","TAE-DESMO","Inclusion Criteria:\n\n* Patients of both sexes aged ≥ 12 years\n* Fibromatosis demsoid symptomatic and in active phase (documented growth at last follow-ups)\n* Patients not eligible for surgery or cryoablation\n* Patients who have had embolization surgery for fibromatosis desmoide from 01\u002F01\u002F2023 to date and all new patients listed for this type of treatment.\n* Signature of informed consent to the study\n\nExclusion Criteria:\n\n* Patients with life expectancy \\\u003C3 months or severely impaired status functional status (ASA 4)\n* Patients with fibromatosis not in active phase, documented clinically and by investigations imaging (MRI, CT)\n* Patients with coagulation deficiency or plateletopenic disease\n* Patients with documented active infection\n* Incompatibility to performing MRI examination.","12 Years",{"count":93,"type":20},20,"Desmoid fibromatoses are rare and locally aggressive mesenchymal tumors. The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial embolization is constituted by several retrospective and prospective studies. These studies report promising results through the use of chemoembolization, that is, arterial embolization using particles loaded with chemotherapy.\n\nInstead, the type of treatment we propose would consist of injection of embolizing material without the use of chemotherapy, based on the positive results we have consistently reported over the years on arterial embolization of musculoskeletal tumors.",[24],[97,98],"Desmoid fibromatosis","Embolization","2025-09-11",{"date":101,"type":35},"2025-09-12",{"date":103,"type":35},"2025-07-01",{"date":105,"type":20},"2029-02",{"name":107,"class":41},"Istituto Ortopedico Rizzoli",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":16,"minAge":17,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":42},"100543442","a-prospective-clinical-study-on-the-safety-and-efficacy-of-radiofrequency-ablation-for-the-treatment-of-patients-with-desmoid-tumors-100543442","NCT06355921","A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors","RFAdesmoid","Inclusion Criteria:\n\n1. Patients with histologically verified diagnosis of dermoid tumor\n2. The presence of progressive, symptomatic or functionally significant DF.\n3. Written Informed consent to participate in the study\n4. Age from 18 to 75 years\n5. The functional status of the patient according to the ECOG 0-2 scale\n6. Normal renal function (estimated creatinine clearance 60 ml\u002Fmin);\n7. Normal level of bilirubin and liver enzymes (AST, ALT - no more than 3 norms);\n8. Left ventricular ejection fraction \\> 55%\n9. Satisfactory bone marrow function (hemoglobin level 9 g\u002Fdl, neutrophil count 1.5 thousand\u002Fml, platelet count \\< 100 thousand\u002Fml);\n\nExclusion Criteria:\n\n1. The inability to obtain informed consent to participate in the study\n2. Synchronous or metachronous cancer\n3. Clinically significant diseases of the cardiovascular system\n4. Clinically significant CNS diseases\n5. Previous grade 2 polyneuropathy and above\n6. Current infection or other severe or systemic disease that increases the risk of complications of therapy\n7. Pregnancy, lactation",true,"75 Years",{"count":118,"type":20},27,"INTERVENTIONAL",[121],"NA","This is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors.\n\nIn the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated using MRI and CT studies and, if solid components of the tumor are detected, repeated surgical treatment is performed followed by active monitoring after 1 month.\n\nIn the absence of a solid component, the effect is estimated by the volume of the necrotic process and monitored in dynamics every 3 months.",[124,24,27],"Desmoid Tumor","NOT_YET_RECRUITING","2024-04-03",{"date":128,"type":35},"2024-04-10",{"date":130,"type":20},"2024-04-01",{"date":132,"type":20},"2028-05-01",{"name":134,"class":41},"Blokhin's Russian Cancer Research Center"]